memoinOncology

Small-cell lung cancer: insights and new treatment options centering around DLL3

The cell surface protein delta-like-ligand 3 (DLL3) is an emerging therapeutic target in neuroendocrine tumors and neuroendocrine carcinomas such as small-cell lung cancer (SCLC). Approximately 75 % of SCLCs express DLL3. Data reported at ESMO 2023 showed that high DLL3 expression is associated with poor overall survival, advanced pathological grade, and a distinct immune landscape across neuroendocrine neoplasms found in the lung, prostate, and bladder.

Read More

Immunotherapy combinations in advanced-stage disease

As is known, immune checkpoint inhibition plays only a limited role after failure of EGFR- or ALK-targeted treatment in patients with advanced NSCLC; this applies to both monotherapy and combinations with chemotherapy as demonstrated by the CheckMate 722 and KEYNOTE-789 trials.

Read More

SPONSORS

This website is intended only for healthcare professionals outside the US, the UK, and Australia.
This website is supported by an unrestricted medical education grant from BeOne, Boehringer Ingelheim and ITM.
© Copyright 2012 -  memoinOncology BY SPRINGER-VERLAG GmbH   |   Projekt: infill healthcare communication GmbH.   |   Alle Rechte vorbehalten.
Die Nutzung der Inhalte ist ausschließlich für den privaten Gebrauch bestimmt. Die über den persönlichen Gebrauch hinausgehende Vervielfältigung und Verbreitung ist nicht gestattet.
;
Accessibility by WAH
Go to Top